No "Phase Zero" for Biotech?
This article was originally published in RPM Report
Executive Summary
The Food & Drug Administration's recent guidance on "Phase Zero" trials has been embraced as a way to help speed up the development process. But for biotech firms, the window of opportunity may be already closed: less than six months after issuing the final guidance, FDA is considering modifications to the Phase Zero policy due to safety concerns.
You may also be interested in...
Phase Zero: "Open for Business"
Despite a setback presented by a small micro-dosing trial in the UK, FDA says its "Phase Zero" program has appropriate safeguards in place and should be pursued by biopharmaceutical companies.
Phase Zero: "Open for Business"
Despite a setback presented by a small micro-dosing trial in the UK, FDA says its "Phase Zero" program has appropriate safeguards in place and should be pursued by biopharmaceutical companies.
A Critical Test for FDA's Critical Path Initiative
FDA wants to reverse the deline in NDA approvals; the agency may have a key ally at a new center in Arizona.